These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 39047611

  • 1. Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy.
    Altıntop MD, Ertorun İ, Akalın Çiftçi G, Özdemir A.
    Eur J Med Chem; 2024 Oct 05; 276():116698. PubMed ID: 39047611
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C, Xu S, Peng L, Zhang B, Zhang H, Hu Y, Zheng P, Zhu W.
    J Enzyme Inhib Med Chem; 2019 Dec 05; 34(1):203-217. PubMed ID: 30835140
    [Abstract] [Full Text] [Related]

  • 3. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
    Tong X, Jiang P, Li Y, Guo L, Zhang HM, Zhang BK, Yan M.
    Chem Pharm Bull (Tokyo); 2019 Aug 01; 67(8):864-871. PubMed ID: 31142691
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Design and synthesis of novel Thiazolo[5,4-b]pyridine derivatives as potent and selective EGFR-TK inhibitors targeting resistance Mutations in non-small cell lung cancer.
    Borude AS, Deshmukh SR, Tiwari SV, Kumar SH, Thopate SR.
    Eur J Med Chem; 2024 Oct 05; 276():116727. PubMed ID: 39094428
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Discovery of highly potent and selective EGFRT790M/L858R TKIs against NSCLC based on molecular dynamic simulation.
    Yang T, Zhang W, Cao S, Sun S, Cai X, Xu L, Li P, Zheng Z, Li S.
    Eur J Med Chem; 2022 Jan 15; 228():113984. PubMed ID: 34794818
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
    Farghaly AM, AboulWafa OM, Baghdadi HH, Abd El Razik HA, Sedra SMY, Shamaa MM.
    Bioorg Chem; 2021 Oct 15; 115():105208. PubMed ID: 34365057
    [Abstract] [Full Text] [Related]

  • 14. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
    Al-Warhi T, El Kerdawy AM, Said MA, Albohy A, Elsayed ZM, Aljaeed N, Elkaeed EB, Eldehna WM, Abdel-Aziz HA, Abdelmoaz MA.
    Drug Des Devel Ther; 2022 Oct 15; 16():1457-1471. PubMed ID: 35607598
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis and anticervical cancer activity of new benzofuran-pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents.
    Abbas HS, Abd El-Karim SS.
    Bioorg Chem; 2019 Aug 15; 89():103035. PubMed ID: 31200286
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFRWT and EGFRT790M inhibitors and apoptosis inducers.
    Gaber AA, Bayoumi AH, El-Morsy AM, Sherbiny FF, Mehany ABM, Eissa IH.
    Bioorg Chem; 2018 Oct 15; 80():375-395. PubMed ID: 29986185
    [Abstract] [Full Text] [Related]

  • 17. The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations.
    Xia Z, Huang R, Zhou X, Chai Y, Chen H, Ma L, Yu Q, Li Y, Li W, He Y.
    Eur J Med Chem; 2021 Nov 15; 224():113711. PubMed ID: 34315040
    [Abstract] [Full Text] [Related]

  • 18. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
    Sherbiny FF, Bayoumi AH, El-Morsy AM, Sobhy M, Hagras M.
    Bioorg Chem; 2021 Nov 15; 116():105325. PubMed ID: 34507234
    [Abstract] [Full Text] [Related]

  • 19. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
    Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I, Redrado M, Catena R, Collantes M, Peñuelas I, Díaz-González JA, Calvo A.
    BMC Cancer; 2010 May 11; 10():188. PubMed ID: 20459769
    [Abstract] [Full Text] [Related]

  • 20. Free energy perturbation guided Synthesis with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
    Karnik KS, Sarkate AP, Tiwari SV, Azad R, Wakte PS.
    Bioorg Chem; 2021 Oct 11; 115():105226. PubMed ID: 34364055
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.